Today, The Ride For Roswell presented by West Herr Automotive Group launched registration for its 2017 event, taking place on Saturday, June 24. Community members of all ages and cycling experience are invited to “choose your route to a cure” by signing up to ride or volunteer at RideForRoswell.org.

The architecture firm that brought the Scott Bieler Clinical Sciences Center to life on the Roswell Park Comprehensive Cancer Center campus has been honored for its efforts. FXFOWLE received the Buffalo/WNY Architecture Award at the 2016 awards gala of AIA Buffalo/WNY, the regional chapter of the American Institute of Architects. The award, recognizing the firm’s work on the 11-story clinical care facility, is the highest honor conferred by the chapter.

Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs despite androgen-deprivation therapy. A team of scientists led by Irwin Gelman, PhD , Professor of Oncology in the Department of Cancer Genetics at Roswell Park Cancer Institute, has identified an 11-gene signature unique to advanced recurrent prostate cancer that they believe will help to identify these aggressive and potentially fatal prostate cancers sooner. The findings have been published online ahead of print in the journal Oncotarget.

Predisposition to cancer and cancer progression can result from gene mutations that cause elevated rates of genetic damage. Similarly, carcinogens, including some that are used in chemotherapy during cancer treatment, act by damaging the DNA. A new study from Roswell Park Cancer Institute offers insights into the mechanisms that can lead to genetic mutations and proposes opportunities for developing prognostic tests for specific blood disorders and blood cancers based on these striking findings.

Metastatic prostate cancer, or prostate cancer that has spread to other organs, is incurable. In new research published in the journal Science, Roswell Park Cancer Institute scientists have identified two gatekeeper genes that allow prostate cancer to progress and resist treatment. Their work illuminates the mechanisms behind lineage plasticity, the ability of prostate cancer to adapt to therapy, and highlights opportunities to disrupt and even reverse this deadly process.